Frank Duong

461 total citations
14 papers, 302 citations indexed

About

Frank Duong is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Frank Duong has authored 14 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Frank Duong's work include Prostate Cancer Treatment and Research (9 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Epigenetics and DNA Methylation (3 papers). Frank Duong is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Epigenetics and DNA Methylation (3 papers). Frank Duong collaborates with scholars based in United States, India and Japan. Frank Duong's co-authors include Neil A. Bhowmick, Rajeev Mishra, Subhash Haldar, Anisha Madhav, Zhenqiu Liu, Priyanka Agarwal, Manisha Tripathi, Krizia Rohena-Rivera, Roberta A. Gottlieb and Edwin M. Posadas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Cancer Research.

In The Last Decade

Frank Duong

13 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank Duong United States	9	151	119	108	101	50	14	302
May Elbanna United States	7	136 0.9×	72 0.6×	85 0.8×	63 0.6×	47 0.9×	16	252
C. Lance Cowey United States	7	193 1.3×	119 1.0×	141 1.3×	113 1.1×	30 0.6×	11	313
Yaping Guan China	11	241 1.6×	156 1.3×	77 0.7×	129 1.3×	51 1.0×	25	431
Hongjuan Xu China	9	233 1.5×	88 0.7×	68 0.6×	155 1.5×	61 1.2×	21	372
Song-Chang Lin United States	6	151 1.0×	120 1.0×	82 0.8×	68 0.7×	23 0.5×	11	280
W Kitonyi Grace Canada	2	114 0.8×	233 2.0×	121 1.1×	86 0.9×	95 1.9×	2	351
Xinbao Zhao China	9	176 1.2×	110 0.9×	64 0.6×	94 0.9×	68 1.4×	12	327
Jian Yuan Goh Singapore	8	164 1.1×	118 1.0×	56 0.5×	117 1.2×	120 2.4×	14	340
Jang-Hyun Choi South Korea	7	195 1.3×	139 1.2×	47 0.4×	91 0.9×	52 1.0×	9	334
Yongchu Sun China	9	194 1.3×	99 0.8×	39 0.4×	135 1.3×	33 0.7×	14	313

Countries citing papers authored by Frank Duong

Since Specialization

Citations

This map shows the geographic impact of Frank Duong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Duong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Duong more than expected).

Fields of papers citing papers by Frank Duong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Duong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Duong. The network helps show where Frank Duong may publish in the future.

Co-authorship network of co-authors of Frank Duong

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Duong. A scholar is included among the top collaborators of Frank Duong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Duong. Frank Duong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Daemen, Anneleen, Natalie Yuen, Xi Chen, et al.. (2025). Abstract 452: ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors. Cancer Research. 85(8_Supplement_1). 452–452.

Daemen, Anneleen, Natalie Yuen, Aleksandr Pankov, et al.. (2024). Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models. Cancer Research. 84(6_Supplement). 6586–6586. 3 indexed citations

Smith, Bethany, Rajeev Mishra, Sandrine Billet, et al.. (2022). Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. Molecular Therapy. 31(1). 78–89. 8 indexed citations

Daemen, Anneleen, Jessica D. Sun, Aleksandr Pankov, et al.. (2021). Abstract 1131: ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models. Cancer Research. 81(13_Supplement). 1131–1131. 3 indexed citations

Vidal, Adriana C., Frank Duong, Lauren E. Howard, et al.. (2020). Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. Anticancer Research. 40(3). 1459–1462. 10 indexed citations

Zavorotinskaya, Tatiana, Brenda Chan, Yuping Chen, et al.. (2020). Abstract 1023: CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cells activation. Cancer Research. 80(16_Supplement). 1023–1023. 2 indexed citations

Haldar, Subhash, Rajeev Mishra, Sandrine Billet, et al.. (2020). Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance. Proceedings of the National Academy of Sciences. 117(15). 8515–8523. 13 indexed citations

Du, Xiaohui, Brenda Chan, Xi Chen, et al.. (2020). Abstract 1037: Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production. Cancer Research. 80(16_Supplement). 1037–1037. 1 indexed citations

Placencio-Hickok, Veronica, Anisha Madhav, Sungjin Kim, et al.. (2019). Soluble CD105 is prognostic of disease recurrence in prostate cancer patients. Endocrine Related Cancer. 27(1). 1–9. 9 indexed citations

10.

Mishra, Rajeev, Subhash Haldar, Veronica R. Placencio, et al.. (2018). Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. Journal of Clinical Investigation. 128(10). 4472–4484. 124 indexed citations

11.

Madhav, Anisha, Allen M. Andres, Frank Duong, et al.. (2018). Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene. 37(32). 4385–4397. 23 indexed citations

12.

Kato, Manabu, Veronica Placencio-Hickok, Anisha Madhav, et al.. (2018). Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene. 38(5). 716–730. 71 indexed citations

13.

Haldar, Subhash, Rajeev Mishra, Manisha Tripathi, et al.. (2016). Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. Scientific Reports. 6(1). 39257–39257. 17 indexed citations

14.

Alkan, Zeynep, Frank Duong, & Wayne Chris Hawkes. (2015). Selenoprotein W controls epidermal growth factor receptor surface expression, activation and degradation via receptor ubiquitination. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1853(5). 1087–1095. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact